Drugs / Krill oil
Krill oil
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06880926 | Apr 2025 → Feb 2026 overdue | osteoarthritis, knee | Qilu Hospital of Shandong University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06580912 | Jan → Dec 2025 | chronic pain syndrome | University of Florida | Completed | No outcome recorded |
| Phase 2 | NCT07604870 | Mar 2023 → Apr 2024 | obesity disorder, polycystic ovary syndrome | Firat University | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Krill oil | “Krill Oil 2 g/day (1 g twice daily, oral administration) for 8 weeks.” NCT07604870 ↗ |
| Known as | AKO | “Antarctic Krill Oil (AKO) as a dietary supplement” NCT06880926 ↗ |
| Known as | Antarctic Krill Oil | “Antarctic Krill Oil (AKO) as a dietary supplement” NCT06880926 ↗ |
| Known as | Superba Boost | “Krill oil (Superba Boost, Aker BioMarine) was administered at 2,000 mg/day (approximately 400 mg EPA and 240 mg DHA) and metformin at 1,000 mg/day.” NCT07604870 ↗ |
| Modality | Other / unclassified | “Krill oil is a marine-derived omega-3 fatty acid supplement rich in EPA, DHA, and phospholipids with antioxidant astaxanthin.” NCT07604870 ↗ |
| Route | Oral | “Oral administration of antarctic krill oil : 2 grams per dose, once daily, for a duration of 24 weeks.” NCT06880926 ↗ |